Bryn Williams-Jones, Director of Exploratory Research at BenevolentAI will be participating to a panel discussion around AI in Life Sciences at the Elixir Bioinformatics Supplier Forum
AI in Life Sciences: what do the machines need to learn and how?
Chair: John P. Overington (Medicine Discovery Catapult)
Bryn Williams-Jones, Benevolent AI
Craig Rhodes, Nvidia
Maria Chatzou, Lifebit
Vibhor Gupta, Pagaea
Bryn is responsible for driving application of AI augmented drug discovery to disease hypothesis generation across the BenevolentAI portfolio bringing together the key scientific and AI strands of research. Before joining BenevolentAI Bryn lead the Open PHACTS IMI project, and is CEO of the Open PHACTS Foundation project building open semantic web infrastructure for drug discovery. Prior to that Bryn worked at Pfizer across a wide range of Therapeutic Areas applying data and computational science to early drug discovery hypothesis generation.